In RET-rearranged non-small cell lung cancer, both types of resistance mechanisms have been described in patients treated with RET-inhibitors (i.e., RET mutations, KRAS and MET amplification) (56, 57). This evidence concerns the gene RET and non-small cell lung carcinoma.